Skip to main content
Premium Trial:

Request an Annual Quote

Aros Offering CLC bio's Enterprise Platform for NGS Data Analysis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish bioinformatics firms CLC bio announced today a deal with Aros Applied Biotechnology for the use of CLC bio's enterprise platform for analyzing next-generation sequencing data.

The deal covers all steps from extraction, sample banking, and analysis to advanced bioinformatics using CLC bio's platform. Aros will now provide its customers the option to receive their data in CLC bio's format, including a time-limited license for CLC Genomics Workbench for assembly and downstream sequence analyses, CLC bio said.

Financial and other terms of the deal were not disclosed.

CLC bio and Aros are already part of a collaboration with other firms in a $5 million project for the large-scale sequence analysis of formalin-fixed, paraffin-embedded tissue samples.

Aros, based in Denmark, specializes on total genomics solutions and is GLP and GCP certified.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.